ReviewBiophysical reviews2026
Nano-based spectroscopic approaches for early diagnosis of Alzheimer's disease: critical insights into amyloid-β and tau biomarker biology and detection tools.
Review in Biophysical reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, and its diagnosis relies primarily on symptoms that emerge long after irreversible neuronal damage. Early detection through reliable quantification of disease-associated protein biomarkers, particularly amyloid-β (Aβ) and tau species, remains a major unmet clinical need. Conventional immunoassays and imaging methods face significant limitations in sensitivity, cost, and suitability for large-scale decentralized screening, thus prompting interest toward nano-enabled spectroscopic biosensing approaches. This review critically examines nano-enabled spectroscopic approaches developed for the detection of Aβ and tau biomarkers, integrating biological context with technological innovation. We compare colloidal nanoparticle-based assays and solid-state nanostructured platforms, with emphasis on surface-enhanced Raman scattering (SERS) and related plasmonic techniques, as well as by the possibility of employing biorecognition strategies. Although many systems achieve ultra-low limits of detection under controlled conditions, we argue that analytical sensitivity alone is insufficient to ensure clinical relevance. Key translational challenges include fabrication reproducibility, batch-to-batch variability, standardization of enhancement metrics, validation in real biological matrices, and the absence of large clinical studies. The increasing incorporation of artificial intelligence for spectral analysis offers opportunities for improved classification, yet introduces concerns regarding dataset size and regulatory validation. By situating nano-spectroscopic biosensing within the biological complexity of early diagnosis of AD biomarkers and the practical constraints of clinical deployment, this review outlines the technological advances achieved to date and the critical steps required for translation: it will depend less on pushing detection limits further and more on achieving reproducibility, manufacturability, cost-effectiveness, and integration into standardized diagnostic workflows. Graphical abstract:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.